9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 801–900 of 1,000
Shi, D., Chen, L., Li, G., Wu, N., Zhang, F., Wang, X., Mu, N., Chen, X., Yang, X., Lu, J., et al. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01333-4 · Cited by 5
Lee, Y. J., Kang, N., Nam, J., Lee, E. G., Ryoo, J., Kwon, S. S., Kim, Y. H., & Kang, H. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299484 · Cited by 5
Butalia, S., Wen, C., Sigal, R. J., Senior, P. A., Quan, H., Chu, L. M., Yeung, R. O., & Kaul, P. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.03.004 · Cited by 5
Yoon, J. H., Hong, A. R., Choi, W., Park, J. Y., Kim, H. K., & Kang, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.3.211 · Cited by 5
Coke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Fatima, Z., Atal, S., Joshi, R. P., & Sadasivam, B. (2022) · Cureus · doi:10.7759/cureus.22141 · Cited by 9
“DOI 10.7759/cureus.22141 (AACE/ACE), National Institute for Health and Care Excellence (NICE) (UK), Indian Council of Medical Research (ICMR) (India) have been recommending the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as the preferred add-on oral therapy, alongside injectable glucagon-like peptide 1 r…”
BackgroundMethodResultInfluentialWhat role for metformin in type 1 diabetes?
(2018) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2018.7.0645 · Cited by 6
Tamaki, J., Ogawa, S., Fujimori, K., Ishii, S., Nakatoh, S., Okimoto, N., Kamiya, K., & Iki, M. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01372-0 · Cited by 5
Ares-Blanco, S., Polentinos-Castro, E., Rodríguez-Cabrera, F. D., Gullón, P., Franco, M., & del Cura-González, I. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.966368 · Cited by 5
Chang, X., Ding, X., Wang, J., Cai, Q., Wang, G., & Liu, J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2226910 · Cited by 5
“DPP4 inhibitors have been widely used as therapeutic agents for type 2 diabetes [11].”
MethodCesta, C. E., Hernández–Díaz, S., Huybrechts, K. F., Bateman, B. T., Vine, S. M., Seely, E. W., & Patorno, E. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5665 · Cited by 5
Song, L., Cao, F., Niu, S., Xu, M. K., Liang, R., Ding, K., Lin, Z., Yao, X., & Liu, D. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01321-8 · Cited by 7
“…of action (e.g., insulin secretagogues, alpha-glucosidase inhibitors, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, sodium-glucose cotransporter 2 inhibitors, insulin or glucagon-like peptide-1 receptor agonists) are often required to provide better and persistent glycemic control [2].”
Chun, K., Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H., Hwang, K., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101504 · Cited by 6
Cuenca, A. M. C., Moreno-Pérez, O., Campuzano-Ruiz, R., Soler, M. J., de Lucas, M. D. G., & Orozco‐Beltrán, D. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102923 · Cited by 5
Oya, J., Nakagami, T., Hasegawa, Y., Kondo, Y., Katamine, A., Shimizu, M., Kubota, R., Suda, R., & Babazono, T. (2024) · Diabetology International · doi:10.1007/s13340-023-00681-7 · Cited by 5
“High insulin doses are associated with an increased risk of weight gain and hypoglycemia [1].”
(2023) · Biointerface Research in Applied Chemistry · doi:10.33263/briac135.445 · Cited by 8
Prescribing pattern and pharmacoeconomic analysis of antidiabetic drugs
Goyal, P., Arora, S., Mittal, N., Mahajan, B., & Kaushal, S. (2019) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20193188 · Cited by 5
Kim, J., Bae, Y., Lee, J., Kim, Y.-S., Kim, Y., You, H., Kim, H.-S., Choi, E.-A., Han, Y.-E., & Kang, H. (2021) · Medicine · doi:10.1097/md.0000000000025045 · Cited by 5
Bando, H. (2022) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2022/asjbccr.6260 · Cited by 7
Changing the diabetes treatment paradigm from glucose control to cardiorenal protection
Ekanayake, P. S., & Mudaliar, S. R. D. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_3114_21 · Cited by 5
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 6
“Two new anti-diabetic classes with documented benefits on glycemic control, cardiovascular outcomes, and over-all mortality have been introduced for type 2 DM within the past two decades: GLP-1 receptor agonists and double-incretin agonists, and SGLT-2 inhibitors [35].”
Steiger, K. G., SWARNA, K. S., Herrin, J. S., & McCoy, R. G. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09784-0 · Cited by 4
Khattab, M. A., Khalil, S. H. A., Bassyouni, A., Fawzy, F., Elgayar, A. H., Elebrashy, I., Elhadidy, K. E., Abdallah, K., El-Hefnawy, M. H., Halawa, M. R., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03091-7 · Cited by 5
“In cases where oral and/or non-insulin injectable anti-diabetic agents alone or in combination are insufficient, insulin-based therapy might be considered as an add-on to the treatment regimen to provide an additional mechanism for controlling blood glucose levels [28, 39, 40].”
InfluentialBertrand, A., Tomek, J., & Rodríguez, B. (2026) · The Journal of Physiology · doi:10.1113/jp287140 · Cited by 5
“Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are commonly administered to T2DM patients to help control blood sugar levels by preventing glucose from being reabsorbed into the kidneys (American Diabetes Association Professional Practice Committee, 2022).”
Metabolic polygenic risk scores for prediction of obesity, type 2 diabetes, and related morbidities
Kim, M. S., Chen, Q., Sui, Y., Yang, X., Wang, S., Weng, L.-C. C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.009 · Cited by 7
Kempeneers, M. A., Issa, Y., Ali, U. A., Bruno, M. J., van Geenen, E. J. M., van Hooft, J. E., Römkens, T. E. H., Siersema, P. D., Spanier, B. W. M., Yahya, I., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001937 · Cited by 4
Maynard, R. D., Korpi-Steiner, N. L., & Cotten, S. W. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac195 · Cited by 5
Ji, L., Luo, Y., Bee, Y. M., Xia, J., Nguyen, K. T., Zhao, W., Chen, L., Chan, S. P., Deerochanawong, C., Lim, S. K., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13392 · Cited by 6
Escobar, J., Monday, O., Vemoori, Y., Yadav, I., Maslamani, A. N. J., Kutabi, S. A., Saeed, L., & Khan, A. (2023) · Cureus · doi:10.7759/cureus.45927 · Cited by 5
Canha, M. I., Ramos, G., Prata, R., Martins, P. L., Ramos, M. V., & Coimbra, J. M. G. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00989-2 · Cited by 4
Sloan, L. A., CHENG, A. Y. Y., Escalada, J., Haluzík, M., & Mauricio, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15425 · Cited by 4
“40 BIs are designed to pro-tract their activity by delaying absorption into systemic circulation and prolonging their half-life.”
BackgroundA study on metformin-induced anemia using red blood cell indices and red cell distribution width
Lingam, S., Gara, H. K., & Vanamali, D. R. (2023) · Assam Journal of Internal Medicine · doi:10.4103/ajoim.ajoim_16_23 · Cited by 4
Alshehri, A., Guan, D., Li, P., Zhang, Y., Ghayee, H. K., Jiao, T., & Shao, H. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.07.003 · Cited by 5
Association of novel antihyperglycaemic drugsversusmetformin with COPD exacerbations
Kimura, Y., Jo, T., Inoue, N., Suzukawa, M., Matsui, H., Sasabuchi, Y., & Yasunaga, H. (2024) · ERJ Open Research · doi:10.1183/23120541.00757-2024 · Cited by 5
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., & Abughosh, S. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102295 · Cited by 4
Dehghani, M., Sadeghi, M., Barzkar, F., Khamseh, M. E., Torshizian, A., & Baradaran, H. R. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70002 · Cited by 5
Matsui, S., Hiraishi, C., Sato, R., Kojima, T., Matoba, K., Fujimoto, K., & Yoshida, H. (2025) · Diabetology International · doi:10.1007/s13340-025-00798-x · Cited by 5
“Based on therapeutic and patient-side clinical factors including comorbidities and complications, metformin therapy and comprehensive lifestyle modifications are generally recommended [3–5].”
Whitlock, R. H., Raizman, Z., Collister, D., Bernier, K. J., Sigurdson, S. M., Tangri, N., Bohm, C. J., Rigatto, C., Komenda, P. V. J., & Yamamoto, J. M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.05.009 · Cited by 4
Kudva, Y. C., & Nair, K. S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.11.016 · Cited by 5
Omar, G., Hegab, W. S. M., & Ghanem, A. (2021) · Journal of Medicine in Scientific Research · doi:10.4103/jmisr.jmisr_100_20 · Cited by 4
Sodium‐glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
Bagheri, B., Yaribeygi, H., Taherifard, E., Talasaz, A. H., Bagheri, H., Darban, M., Tabrizi, R., Najafi, S., Khodadost, M., & Akbari, M. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12852 · Cited by 4
“73 m(2).(37) Despite the promising impact of SGLT2is in patients with CKD, its use should be avoided in patients with end-stage kidney disease.”
BackgroundGoak, I. S., Lee, J. A., Jeong, M. H., Moon, S. J., & Kim, M. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s393675 · Cited by 6
Zhang, X., Yip, T. C., Tse, Y., Hui, V. W., Li, G., Lin, H., Liang, L. Y., Lai, J. C., Lai, M. S., Cheung, J. T. K., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17428 · Cited by 4
Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
Kourtidou, C., Rafailidis, V. D., Varouktsi, G., Kanakis, E., Liakopoulos, V., Vyzantiadis, T., Savopoulos, C. G., Marinaki, S., Stangou, M. J., & Τζιόμαλος, Κ. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030536 · Cited by 5
Schwartz, X., Porter, B. A., Gilbert, M. P., Sullivan, A., Long, B., & Lentz, S. A. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2023.04.018 · Cited by 5
Weeda, E. R., Ward, R. C., Gebregziabher, M., Chandler, O., Strychalski, M. L., Axon, R. N., & Taber, D. J. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.04.006 · Cited by 4
Chonko, K., Russo‐Alvarez, G., Isaacs, D. M., Wang, L., & Soric, A. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5456 · Cited by 5
Zhang, Q., Zhang, Q., Liu, Y., Yang, S., & Yu, L. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03719-6 · Cited by 4
Hong, Y., Jeon, Y., Choi, Y., Chung, T. K., & Lee, H. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01518-x · Cited by 5
“Many clinical practice guidelines (CPGs) for T2DM recommend metformin as an initial pharmacologic treatment, followed by stepwise addition of other medications [1–4].”
BackgroundType 2 diabetes mellitus: current diagnosis and treatment
Erdin, Z., & Çifci, A. (2023) · Journal of Translational and Practical Medicine · doi:10.51271/jtpm-0053 · Cited by 4
Olson, J., Mo, K., Schmerler, J., Durand, W. M., Kebaish, K. M., Skolasky, R. L., & Neuman, B. J. (2024) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001595 · Cited by 4
Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide
Hou, Y., Fan, Y., Cheng, Y., Peng, X., Shan, C., & Yang, Y. (2024) · International Heart Journal · doi:10.1536/ihj.23-576 · Cited by 4
“24) Currently, liraglutide and dulaglutide are commonly used GLP-1RAs in clinical practice.”
Tiwari, R. K., Ahmad, A., Chadha, M., Saha, K., Verma, H., Borgohain, K., & Shukla, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998294919240506044544 · Cited by 5
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
Mazzilli, R., Zamponi, V., Mancini, C., Giorgini, B., Golisano, B., Mikovic, N., Pecora, G., Russo, F., Martiradonna, M., Paravani, P., et al. (2025) · Endocrine · doi:10.1007/s12020-024-04149-9 · Cited by 4
Phonyiam, R., Teng, C., Sullivan, C., Palmquist, A. E. L., Hodges, E. A., Cortés, Y. I., & Baernholdt, M. (2025) · Belitung Nursing Journal · doi:10.33546/bnj.3639 · Cited by 4
Karakasis, P., Patoulias, D., Fragakis, N., & Gómez‐Huelgas, R. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.02.023 · Cited by 4
Hatano, M., Okada, A., Sasabuchi, Y., Ishikura, H., Tanaka, T., Saito, T., Tanaka, S., & Yasunaga, H. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf136 · Cited by 5
Gan, L., Chen, P., Zhang, Z., He, X., Wu, X., Chen, Z., Wei, Q., & Wu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-94360-z · Cited by 4
Hutchins, A. M. (2022) · Food Science & Nutrition Technology · doi:10.23880/fsnt-16000211 · Cited by 4
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD
Muanda, F. T., Weir, M. A., Bathini, L., Clemens, K. K., Perkovic, V., Sood, M. M., McArthur, E., Sontrop, J. M., Kim, R. B., & Garg, A. X. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08310520 · Cited by 4
Dilatación gástrica aguda asociada al empleo de semaglutida, un análogo de GLP-1
Segura, P. S., Lázaro, Y. A., Tapia, S. M., Puerta, J., & Domingo, J. J. S. (2021) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.11.021 · Cited by 4
Harada, M., Nishi, T., Maeda, T., Tanno, K., Nishiya, N., & Arima, H. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100961 · Cited by 5
Stone, R., Oganesyan, A., Marco, N., Smith, R. L., & Hoffman, J. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.62 · Cited by 4
Bando, H. (2022) · Diabetes Research - Open Journal · doi:10.17140/droj-8-e017 · Cited by 5
Takahashi, H., Suganuma, Y., Ohno, T., & Nishimura, R. (2022) · Diabetology International · doi:10.1007/s13340-022-00577-y · Cited by 4
Shimizu, N., Ogawa, A., Hayashi, A., & Shichiri, M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108225 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Cytokine Profile in Patients With Maturity-onset Diabetes of the Young (MODY)
DIREN, A., Demirci, D. K., Gül, N., Karacanli, B., Baykut, A., Tütüncü, Y., Öztürk, O., Satman, İ., & Yılmaz, H. (2022) · In Vivo · doi:10.21873/invivo.12985 · Cited by 5
Conceptos Actuales de la Terapia Con Insulina.
Montero, G. J., Barakat, M. V., & Solórzano, M. L. C. (2022) · Revista Ciencia y Salud Integrando conocimientos · doi:10.34192/cienciaysalud.v6i3.416 · Cited by 8
Use of Patient-Reported Outcomes for Assessing Diabetes Outcomes
Kim, H., Shah, K. P., & Buettner, C. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.05.001 · Cited by 4
Alem, M. M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11549 · Cited by 6
Abu‐Alfa, A. K., Atallah, P., Azar, S. T., Dagher, E., Echtay, A. S., Amm, M., Hazkial, H. G., Kassab, R., Medlej, R., & Mohamad, M. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01340-x · Cited by 4
Cheung, J. T. K., Yang, A., Wu, H., Lau, E. S. H., Shi, M., Kong, A. P. S., Ronald, C. W., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110203 · Cited by 4
Recognizing the True Value of Testosterone Therapy in Health Care
Morgentaler, A., Traish, A. M., Barua, R. S., Dandona, P., Dhindsa, S., Khera, M., & Saad, F. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0021 · Cited by 6
Salinas-Martı́nez, A. M., Montes, A. G. J., Morado, Y. R., Cordero-Franco, H. F., Garza, F., Oyervides, L. C. H., & Núñez‐Rocha, G. M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1058828 · Cited by 4
Khan, R. A., Patel, N., Folajimi, A., Bansari, R. B., Patel, V., Komminni, P. K., Palleti, S. K., & Hirani, S. (2023) · Cureus · doi:10.7759/cureus.35014 · Cited by 11
Suits, A., Gudoor, R., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4010011 · Cited by 5
Comprehensive Insulin and Noninsulin Injectable Diabetes Medication Resource: Update
Holt, K. M., Isaacs, D. M., RINKER, J. K., Cox, M. A., & Stahnke, A. M. (2023) · ADCES in Practice · doi:10.1177/2633559x231159892 · Cited by 4
Erukulapati, R. S., Ganguri, M., Menon, A. S., Ayyagari, U., Jayapaul, M. K., Gurazada, K. C., Nalla, S., Srinath, A., Sampath, S. K., Manohar, S. P., et al. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0061 · Cited by 6
Zhang, J., Spall, H. G. C. V., Li, L., Khan, M. S., Pandey, A., Thabane, L., Bai, X., Wang, Y., Lip, G. Y. H., & Li, G. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102804 · Cited by 4
Ouchi, D., Giner‐Soriano, M., Vilaplana-Carnerero, C., Monfà, R., Torres, F., & Morros, R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110777 · Cited by 4
Nanoscale MOF–Protein Composites for Theranostics
Zhou, X., Zhong, Z., Xu, N., & Zhong, S. (2023) · Crystals · doi:10.3390/cryst13081229 · Cited by 4
Harris, S. B., Mohammedi, K., Bertolini, M., Carlyle, M. H., Walker, V., Zhou, F. L., Anderson, J. E., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15240 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 5
Sulfonylureas as treatment choice in Diabetes Mellitus : Where are we now?
Manta, A., & Peppa, Μ. (2019) · Diabetes Updates · doi:10.15761/du.1000124 · Cited by 5
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
Misher, A. D., Ampuero, A., Phan, R., Aziz, S., Ebong, E., Braich, J., Dyches, K., & Southwood, R. L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001164 · Cited by 4
Index of C-peptide / glucose ratio for Carbo70 can be useful in clinical practice for diabetes
Bando, H., Ebe, K., Bando, M., & Yonei, Y. (2018) · Journal of Clinical Investigation and Studies · doi:10.15761/jcis.1000102 · Cited by 4
Wadhawan, M., Chhabra, V., Katiyar, A., Sharma, V., Khuntia, B. K., Rathore, S., Kaur, P., & Sharma, G. (2021) · Research Square · doi:10.21203/rs.3.rs-954990/v1 · Cited by 8
Nicholas, S. B., Alicic, R. Z., & Shen, J. I. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100590 · Cited by 4
Metformin and Infections: What Is the Next Step in This Decades-Long Story?
Goto, M., & Perencevich, E. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac903 · Cited by 4
Sato, A., Takei, M., Hiramatsu, K., Takeda, T., Miyamoto, T., Yamazaki, M., Sato, Y., & Komatsu, M. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3632 · Cited by 3
Actualización en el uso de insulinas para el médico de familia
López‐Simarro, F., Cols-Sagarra, C., Bravo, J. J. M., Cañís-Olivé, J., Hernández-Teixidó, C., & Loro, M. B. G. M. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.04.011 · Cited by 7
Doğruel, H., Atlım, H. T., Aydemir, M., Yılmaz, N., & Sarı, R. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03262-w · Cited by 4
Scott, S. N., HAYES, C. A., Zeuger, T., Davies, A. P., Andrews, R. C., & Cocks, M. S. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0015 · Cited by 6
Ehrmann, D., Kulzer, B., Wienbarg, I., Sieber, J., Weber, S., Haak, T., & Hermanns, N. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231175920 · Cited by 6
Ortega-Montiel, J., Montoya, A., Soria-Saucedo, R., Gallegos-Carrillo, K., Ramírez‐Palacios, P., Salmerón, J., & Salazar-Martínez, E. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/5555274 · Cited by 4
Sanvee, S. C. J., Kombate, B., Kantati, Y. T., Kpoyizoun, P. K., Badjabaïssi, E., Assih, M., Diallo, A., & Bakoma, B. (2024) · Pharmacognosy Journal · doi:10.5530/pj.2024.16.91 · Cited by 3
“Managing the disorder and it’s complications can then be done by lowering those levels through increasing muscle absorption of the blood glucose or by impeding the glucose absorption by the intestine for examples 25,26 .”
BackgroundRecent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors
Demirkiran, C., Demiryürek, Ş., & Demiryürek, A. T. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575325210240805092741 · Cited by 4
SGLT2 inhibitors: Exploring the effects in humans and horses
Sundra, T., Matthews, V. B., Harris, P. A., & Rendle, D. I. (2024) · Equine Veterinary Education · doi:10.1111/eve.14071 · Cited by 3
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.